{"id":58884,"date":"2026-03-05T17:14:28","date_gmt":"2026-03-05T09:14:28","guid":{"rendered":"https:\/\/flcube.com\/?p=58884"},"modified":"2026-03-05T17:14:29","modified_gmt":"2026-03-05T09:14:29","slug":"hutchmed-initiates-phase-i-iia-trial-for-hmpl-a580-second-antibody-targeted-triggered-conjugate-targets-egfr-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58884","title":{"rendered":"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors"},"content":{"rendered":"\n<p><strong>HutchMed (China) Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/0013:HKG\">HKG: 0013<\/a>) announced the initiation of a <strong>Phase I\/IIa clinical trial<\/strong> for <strong>HMPL-A580<\/strong>, the company&#8217;s <strong>second Antibody-Targeted Triggered Conjugate (ATTC)<\/strong>, in patients with <strong>unresectable advanced or metastatic solid tumors<\/strong>. The study will enroll patients across <strong>China and the United States<\/strong>, marking HutchMed&#8217;s continued expansion into novel antibody-drug conjugate (ADC) modalities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-overview\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase I\/IIa (dose escalation + expansion)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable advanced or metastatic solid tumors<\/td><\/tr><tr><td><strong>Geography<\/strong><\/td><td>China and United States (dual-territory initiation)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>HMPL-A580 (second ATTC in HutchMed pipeline)<\/td><\/tr><tr><td><strong>Trial Initiation<\/strong><\/td><td>4 Mar 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-mechanism\">Technology Platform &amp; Mechanism<\/h2>\n\n\n\n<p><strong>ATTC Architecture:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antibody Component:<\/strong> Anti-EGFR monoclonal antibody for tumor-specific targeting<\/li>\n\n\n\n<li><strong>Payload:<\/strong> Highly selective and potent <strong>PI3K\/PIKK small molecule inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Linker:<\/strong> Cleavable linker enabling intracellular payload release<\/li>\n\n\n\n<li><strong>Target:<\/strong> EGFR (highly expressed across multiple solid tumor types; recognized driver of oncogenesis and disease progression)<\/li>\n<\/ul>\n\n\n\n<p><strong>Mechanistic Synergy:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Pathway Blockade:<\/strong> EGFR surface inhibition + intracellular PAM pathway (PI3K\/AKT\/mTOR) disruption<\/li>\n\n\n\n<li><strong>Resistance Overcoming:<\/strong> Preclinical data demonstrates <strong>synergistic anti-tumor activity<\/strong> when PI3K\/PIKK inhibition combines with anti-EGFR therapy<\/li>\n\n\n\n<li><strong>First-in-Class Position:<\/strong> Novel ATTC format distinct from traditional ADCs (antibody-drug conjugates) and existing EGFR-targeted therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>HMPL-A580 Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>Selectivity<\/strong><\/td><td>Highly selective PI3K\/PIKK inhibitor payload<\/td><\/tr><tr><td><strong>Potency<\/strong><\/td><td>Potent PAM pathway blockade at tumor site<\/td><\/tr><tr><td><strong>Synergy<\/strong><\/td><td>Enhanced activity vs. anti-EGFR monotherapy or PI3K inhibitor alone<\/td><\/tr><tr><td><strong>Resistance Mechanism<\/strong><\/td><td>Addresses EGFR TKI resistance via parallel pathway inhibition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-pipeline-position\">Strategic Context &amp; Pipeline Position<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Pipeline Depth<\/strong><\/td><td>Second ATTC following HMPL-453 (first-generation asset); validates platform reproducibility<\/td><\/tr><tr><td><strong>Geographic Strategy<\/strong><\/td><td>Dual China\/U.S. initiation accelerates global development timeline and FDA engagement<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Positions against EGFR ADCs (e.g., patritumab deruxtecan) and PI3K inhibitors (alpelisib) with differentiated dual-mechanism approach<\/td><\/tr><tr><td><strong>Combination Potential<\/strong><\/td><td>Platform enables future pairings with checkpoint inhibitors or chemotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Outlook:<\/strong> EGFR-targeted therapies represent <strong>$15+ billion market<\/strong>; HMPL-A580&#8217;s resistance-overcoming profile targets TKI-failed patient segment<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> HutchMed leveraging internal biologics capabilities at Shanghai Pudong facility for ATTC production<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, enrollment projections, and therapeutic potential for HMPL-A580. Actual results may differ due to dose-limiting toxicity findings, regulatory feedback, and competitive dynamics in the solid tumor ADC landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030400737_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030400737_c.\"><\/object><a id=\"wp-block-file--media-190cdea6-b8f7-4174-a679-86776aed82a3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030400737_c.pdf\">2026030400737_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030400737_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-190cdea6-b8f7-4174-a679-86776aed82a3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\/IIa clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,1105,285,1104,25],"class_list":["post-58884","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-0013","tag-hutchmed","tag-nasdaq-hcm","tag-potential-first-in-class"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\/IIa clinical trial for HMPL-A580, the company&#039;s second Antibody-Targeted Triggered Conjugate (ATTC), in patients with unresectable advanced or metastatic solid tumors. The study will enroll patients across China and the United States, marking HutchMed&#039;s continued expansion into novel antibody-drug conjugate (ADC) modalities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58884\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\/IIa clinical trial for HMPL-A580, the company&#039;s second Antibody-Targeted Triggered Conjugate (ATTC), in patients with unresectable advanced or metastatic solid tumors. The study will enroll patients across China and the United States, marking HutchMed&#039;s continued expansion into novel antibody-drug conjugate (ADC) modalities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58884\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T09:14:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T09:14:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58884#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58884\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed Initiates Phase I\\\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors\",\"datePublished\":\"2026-03-05T09:14:28+00:00\",\"dateModified\":\"2026-03-05T09:14:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58884\"},\"wordCount\":384,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 0013\",\"HutchMed\",\"NASDAQ: HCM\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58884#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58884\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58884\",\"name\":\"HutchMed Initiates Phase I\\\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-05T09:14:28+00:00\",\"dateModified\":\"2026-03-05T09:14:29+00:00\",\"description\":\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\\\/IIa clinical trial for HMPL-A580, the company's second Antibody-Targeted Triggered Conjugate (ATTC), in patients with unresectable advanced or metastatic solid tumors. The study will enroll patients across China and the United States, marking HutchMed's continued expansion into novel antibody-drug conjugate (ADC) modalities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58884#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58884\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58884#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed Initiates Phase I\\\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\/IIa clinical trial for HMPL-A580, the company's second Antibody-Targeted Triggered Conjugate (ATTC), in patients with unresectable advanced or metastatic solid tumors. The study will enroll patients across China and the United States, marking HutchMed's continued expansion into novel antibody-drug conjugate (ADC) modalities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58884","og_locale":"en_US","og_type":"article","og_title":"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors","og_description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\/IIa clinical trial for HMPL-A580, the company's second Antibody-Targeted Triggered Conjugate (ATTC), in patients with unresectable advanced or metastatic solid tumors. The study will enroll patients across China and the United States, marking HutchMed's continued expansion into novel antibody-drug conjugate (ADC) modalities.","og_url":"https:\/\/flcube.com\/?p=58884","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T09:14:28+00:00","article_modified_time":"2026-03-05T09:14:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58884#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58884"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors","datePublished":"2026-03-05T09:14:28+00:00","dateModified":"2026-03-05T09:14:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58884"},"wordCount":384,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 0013","HutchMed","NASDAQ: HCM","Potential first-in-class"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58884#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58884","url":"https:\/\/flcube.com\/?p=58884","name":"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-05T09:14:28+00:00","dateModified":"2026-03-05T09:14:29+00:00","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I\/IIa clinical trial for HMPL-A580, the company's second Antibody-Targeted Triggered Conjugate (ATTC), in patients with unresectable advanced or metastatic solid tumors. The study will enroll patients across China and the United States, marking HutchMed's continued expansion into novel antibody-drug conjugate (ADC) modalities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58884#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58884"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58884#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed Initiates Phase I\/IIa Trial for HMPL-A580 \u2013 Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58884"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58884\/revisions"}],"predecessor-version":[{"id":58888,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58884\/revisions\/58888"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}